Abstract
Objective: Patients with bladder cancer (BC) are at risk of developing upper tract urothelial carcinoma (UTUC). Therefore, CT urography is recommended for follow-up. To avoid intravenous contrast agents, retrograde pyelography (RPG) is an alternative. However, it is still unclear whether RPG increases the incidence of UTUC. The aim of this study was to investigate the impact of RPG in the presence of BC on the risk of developing UTUC. Patients and Methods: Retrospectively analysing a total of 3,680 RPGs between 2009 and 2016, all patients with simultaneous BC (group 1) and those without synchronous BC (group 2) during RPG were compared. All patients were risk stratified according to the EORTC bladder calculator. In patients without BC during RPG, risk stratification was based on the worst prior tumour characteristics. Results: A total of 145 patients with a history of BC were analysed. Of these, 112 patients underwent RPG with simultaneous BC. UTUC developed in 6 of 112 patients (5.4%) and 58.9% (66/112) had high-risk BC according to the EORTC bladder calculator. In the control group, one out of 33 (3%) patients with metachronous high-risk BC developed UTUC. Conclusions: Using RPG in the presence of BC did not increase the risk of UTUC. Due to the predominant number of high-risk/high-grade tumours, individual tumour biology appears to be the primary driver for the development of UTUC.
References
1.
Babjuk
M
, Burger
M
, Compérat
E
, Gontero
P
, Mostafid
AH
, Palou
J
, EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2020
. European association of urology guidelines 2020
. ed. Arnhem, The Netherlands
: European Association of Urology Guidelines Office
; 2020
.2.
Cosentino
M
, Palou
J
, Gaya
JM
, Breda
A
, Rodriguez-Faba
O
, Villavicencio-Mavrich
H
. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma
. World J Urol
. 2013 Feb 1
;31
(1
):141
–5
. .3.
Singla
N
, Fang
D
, Su
X
, Bao
Z
, Cao
Z
, Jafri
SM
, A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States
. J Urol
. 2017
;197
(5
):1208
–13
. .4.
Palou
J
, Rodríguez-Rubio
F
, Huguet
J
, Segarra
J
, Ribal
MJ
, Alcaraz
A
, Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor
. J Urol
. 2005
;174
(3
):859
–61
. .5.
Sylvester
RJ
, van der Meijden
AP
, Oosterlinck
W
, Witjes
JA
, Bouffioux
C
, Denis
L
, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials
. Eur Urol
. 2006 Mar 1
;49
(3
):466
–7
. .6.
Rouprêt
M
, Babjuk
M
, Burger
M
, Compérat
E
, Cowan
NC
, Gontero
P
, EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma 2020
. European association of urology guidleines 2020
. ed. Arnhem, The Netherlands
: European Association of Urology Guidelines Office
; 2020
.7.
Van Der Molen
AJ
, Cowan
NC
, Mueller-Lisse
UG
, Nolte-Ernsting
CC
, Takahashi
S
, Cohan
RH
. CT urography: definition, indications and techniques. a guideline for clinical practice
. Eur Radiol
. 2007 Nov 1
;18
(1
):4
. .8.
Blick
CG
, Nazir
SA
, Mallett
S
, Turney
BW
, Onwu
NN
, Roberts
IS
, Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic
. BJU Int
. 2012
;110
(1
):84
–94
. .9.
Nolte-Ernsting
C
, Cowan
N
. Understanding multislice CT urography techniques: many roads lead to Rome
. Eur Radiol
. 2006 Dec 1
;16
(12
):2670
–86
. .10.
Mohapatra
A
, Vemana
G
, Bhayani
S
, Baty
J
, Vetter
J
, Strope
SA
. Trends in the utilization of imaging for upper tract urothelial carcinoma
. Urol Oncol
. 2016 May 1
;34
(5
):236
–8
. .11.
Hasebroock
KM
, Serkova
NJ
. Toxicity of MRI and CT contrast agents
. Expert Opin Drug Metab Toxicol
. 2009 Apr
;5
(4
):403
–16
. .12.
Kiss
B
, Furrer
MA
, Wuethrich
PY
, Burkhard
FC
, Thalmann
GN
, Roth
B
. Stenting prior to cystectomy is an independent risk factor for upper urinary tract recurrence
. J Urol
. 2017
;198
(6
):1263
–8
. .13.
Guo
RQ
, Hong
P
, Xiong
GY
, Zhang
L
, Fang
D
, Li
XS
, Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis
. BJU Int
. 2018 Feb
;121
(2
):184
–93
. .14.
Erman
A
, Kapun
G
, Novak
S
, Pavlin
M
, Dražić
G
, Drobne
D
, How cancer cells attach to urinary bladder epithelium in vivo: Study of the Early Stages of Tumorigenesis in an orthotopic mouse bladder tumor model
. Histochem Cell Biol
. 2019 Mar
;151
(3
):263
–73
. .15.
Sountoulides
P
, Pyrgidis
N
, Brookman-May
S
, Mykoniatis
I
, Karasavvidis
T
, Hatzichristou
D
. Does ureteral stenting increase the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors? A systematic review and meta-analysis
. J Urol
. 2021 Apr
;205
(4
):956
–66
. .16.
Miest
TS
, Sharma
V
, Boeri
L
, Tollefson
MK
, Thompson
RH
, Boorjian
SA
, Does ureteral stent drainage prior to cystectomy increase the risk of subsequent upper tract urothelial carcinoma and ureteral complications?
Urology
. 2021 Jul
;153
:215
–20
. Epub 2020 Aug 5.17.
Bosshard
P
, Thalmann
GN
, Roth
B
. Instillation therapies for urothelial carcinoma of the upper urinary tract
. Urologe A
. 2019 Jan
;58
(1
):25
–9
. .18.
Lindert
KA
, Terris
MK
. Effect of contrast material on transitional cell carcinoma viability
. Urology
. 2000 Nov 1
;56
(5
):876
–9
. .19.
Macleod
LC
, Pham
KN
, Agoff
SN
, Dahl
KL
, Pritchett
TR
, Corman
JM
. Cytologic persistence of malignant cells after transurethral resection of bladder tumors: implications for concomitant manipulation of the urinary tract at the time of endoscopic resection
. Cancer Cytopathol
. 2017 Feb
;125
(2
):114
–9
. .20.
Herr
HW
, Cookson
MS
, Soloway
SM
. Upper tract tumors in patients with primary bladder cancer followed for 15 years
. J Urol
. 1996 Oct
;156
(4
):1286
–7
. .21.
Hurle
R
, Losa
A
, Manzetti
A
, Lembo
A
. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients
. Urology
. 1999 Jun
;53
(6
):1144
–8
. .22.
Millan-Rodriguez
F
, Chechile-Toniolo
G
, Salvador-Bayarri
J
, Huguet-Perez
J
, Vicente-Rodriguez
J
. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups
. J Urol
. 2000 Oct
;164
(4
):1183
–7
.23.
Huguet-Perez
J
, Palou
J
, Millan-Rodriguez
F
, Salvador-Bayarri
J
, Villavicencio-Mavrich
H
, Vicente-Rodriguez
J
. Upper tract transitional cell carcinoma following cystectomy for bladder cancer
. Eur Urol
. 2001 Sep
;40
(3
):318
–23
.24.
Wright
JL
, Hotaling
J
, Porter
MP
. Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis
. J Urol
. 2009 Mar
;181
(3
):1035
–9
; discussion 39. .25.
Krabbe
LM
, Lotan
Y
, Bagrodia
A
, Gayed
BA
, Darwish
OM
, Youssef
RF
, Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?
J Urol
. 2014 Apr
;191
(4
):926
–31
. .26.
Krabbe
LM
, Bagrodia
A
, Westerman
ME
, Gayed
BA
, Haddad
AQ
, Sagalowsky
AI
, Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?
World J Urol
. 2016 Jan
;34
(1
):105
–12
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
